Showing 4971-4980 of 5910 results for "".
- Alcon to Showcase Innovations at #Academy20 that Support Recovery and Growth for Eye Care Practiceshttps://modernod.com/news/alcon-to-showcase-innovations-at-academy20-that-support-recovery-and-growth-for-eye-care-practices/2478379/Alcon will highlight leading innovations and clinical research at the 2020 American Academy of Optometry (#Academy20) meeting taking place virtually from October 7-22, 2020. The company’s virtual program will feature updates on its most important innovations, including Precision1 one-day contact
- Sun Ophthalmics to Present E-Posters at AAOpthttps://modernod.com/news/sun-ophthalmics-to-present-e-posters-at-aaopt/2478370/Sun Ophthalmics announced that is will be present several e-posters at the upcoming virtual AAOpt meeting being held this week. Author Presentation October 7, 4-6 pm, Session: Anterior Segment I Toyos M, Shen Lee B, Schechter B, Ogundele A, Gupta P, K
- TearSolutions Announces Results From Primary Sjögren’s Syndrome Trial and Appoints Anil Asrani President and CEOhttps://modernod.com/news/tearsolutions-announces-results-from-primary-sjocc88grens-syndrome-trial-and-appoints-anil-asrani-president-and-ceo/2478369/TearSolutions announced the completion and preliminary outcomes of a phase 1/2 trial of Lacripep in Primary Sjögren’s Syndrome (PSS) patients. The trial was designed to test proof of concept and optimize the design f
- Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitishttps://modernod.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/Tarsius Pharma announced that the GADOT 20/20 trial of its novel TRS01 drug for treating active anterior noninfectious uveitis, demonstrated significant improvement in critical measures such as Anterior Chamber Cells, pain reduction and increased visual acuity. The GADOT 20/20 trial was a
- Beovu Now Available in Canada, Receives Positive Reimbursement Recommendationhttps://modernod.com/news/beovu-now-available-in-canada-receives-positive-reimbursement-recommendation/2478363/Novartis Pharmaceuticals Canada has announced that Beovu (brolucizumab injection) is now available in Canada for the treatment of wet age-related macular degeneration (AMD). The anti-VEGF therapy for wet AMD offers the option for eligible patients to start on 3-mo
- New Company TearRestore Launches Reusable Heat Packs to Target the Meibomian Glandshttps://modernod.com/news/new-company-tearrestore-launches-reusable-heat-packs-to-target-the-meibomian-glands/2478355/New company TearRestore is seeking to simplify warm compress treatment by offering the proprietary TearRestore product. The product utilizes specially designed reusable heat packs to target the Meibomian glands while
- Centricity Vision Appoints Jim Mazzo to its Board of Directorshttps://modernod.com/news/centricity-vision-appoints-jim-mazzo-to-its-board-of-directors/2478353/Centricity Vision announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mr. Mazzo has over 40 years of experience in the ophthalmology industry. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North
- Biotech Healthcare Launches Optiflex TRIO Trifocal IOL in Europehttps://modernod.com/news/biotech-healthcare-launches-optiflex-trio-trifocal-iol/2478350/Switzerland-based Biotech Healthcare has announced the European launch of the Optiflex Trio, a diffractive-refractive trifocal toric IOL designed to treat presbyopia and with astigmatism. Its unique diffraction pattern gives a balanced light distribution at all three distances: near, intermediate
- Employers Will Need to Respond Carefully Amid Roller Coaster of Health Costs During COVID-19https://modernod.com/news/employers-will-need-to-respond-carefully-amid-roller-coaster-of-health-costs-during-covid-19/2478345/Employers will likely see drops in year-over-year medical costs in 2020 after large numbers of employees deferred healthcare services due to the COVID-19 pandemic, according to a FierceHealthcare report. Despite the significant drop in the use of healthcare services in 2020, employer heal
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be